Solithromycin is being investigated primarily for its use in treating bacterial respiratory tract infections, especially community-acquired bacterial pneumonia (CABP). It shows potent activity against common pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, and atypical bacteria like Legionella pneumophila and Mycoplasma pneumoniae. Due to its ability to penetrate lung tissue effectively and its activity against macrolide-resistant strains, solithromycin offers a potential alternative in cases where standard antibiotics may fail. It has been developed in both intravenous and oral forms, allowing for flexible treatment options from hospital to outpatient settings. Clinical trials have focused on its efficacy and safety profile, positioning it as a candidate for front-line therapy in respiratory infections with growing antimicrobial resistance concerns.